• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor.

作者信息

Knepp V M, Whatley J L, Muchnik A, Calderwood T S

机构信息

Syntex Development Research, Palo Alto California 94303, USA.

出版信息

PDA J Pharm Sci Technol. 1996 May-Jun;50(3):163-71.

PMID:8696780
Abstract

Peroxides present in non-ionic surfactants used to stabilize certain recombinant protein formulations (e.g. polysorbate 80) can result in the oxidative degradation of proteins. In this study, the ability of various pharmaceutically acceptable antioxidants to prevent the oxidative degradation of two therapeutic proteins, recombinant human Ciliary Neurotrophic Factor (rhCNTF) and recombinant human Nerve Growth Factor (rhNGF), caused by alkyl hydroperoxides and hydrogen peroxide was studied. For rhCNTF, the rank order of effectiveness of the antioxidants tested was: thiols (cysteine, glutathione, thioglycerol) >> thioethers (methionine). Other parenterally acceptable antioxidants (ascorbic acid, propyl gallate and sodium bisulfite) destabilized the protein. The thiol antioxidants (cysteine and glutathione) were also the most effective antioxidants for rhNGF; however, in contrast to rhCNTF, ascorbic acid did not destabilize rhNGF. The rank order of effective antioxidants for rhNGF was: thiols (cysteine, glutathione) > > thioethers (methionine) > ascorbic acid.

摘要

相似文献

1
Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor.
PDA J Pharm Sci Technol. 1996 May-Jun;50(3):163-71.
2
A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.一项在肌萎缩侧索硬化症中使用重组人睫状神经营养(rhCNTF)因子的安慰剂对照试验。rhCNTF ALS研究组。
Ann Neurol. 1996 Feb;39(2):256-60. doi: 10.1002/ana.410390215.
3
Effects of antioxidants on the hydrogen peroxide-mediated oxidation of methionine residues in granulocyte colony-stimulating factor and human parathyroid hormone fragment 13-34.抗氧化剂对过氧化氢介导的粒细胞集落刺激因子和人甲状旁腺激素片段13 - 34中甲硫氨酸残基氧化的影响。
Pharm Res. 2004 Dec;21(12):2377-83. doi: 10.1007/s11095-004-7692-4.
4
Re: Pharmacokinetics and pharmacodynamics of rHCNTF in rodents.关于:重组人睫状神经营养因子(rHCNTF)在啮齿动物中的药代动力学和药效学
Ann Neurol. 1996 Apr;39(4):552-4. doi: 10.1002/ana.410390420.
5
Methionine oxidation and apoptosis induction by ascorbate, gallate and hydrogen peroxide.甲硫氨酸氧化以及抗坏血酸、没食子酸盐和过氧化氢诱导的细胞凋亡
Anticancer Res. 1997 Jul-Aug;17(4A):2565-70.
6
Production of hydrogen peroxide and methionine sulfoxide by epigallocatechin gallate and antioxidants.表没食子儿茶素没食子酸酯和抗氧化剂产生过氧化氢和甲硫氨酸亚砜
Anticancer Res. 2001 Jul-Aug;21(4A):2633-41.
7
Stability and interactions of recombinant human nerve growth factor in different biological matrices: in vitro and in vivo studies.重组人神经生长因子在不同生物基质中的稳定性及相互作用:体外和体内研究
Drug Metab Dispos. 2000 May;28(5):590-7.
8
Effect of antioxidants and silicates on peroxides in povidone.抗氧化剂和硅酸盐对聚维酮中过氧化物的影响。
J Pharm Sci. 2012 Jan;101(1):127-39. doi: 10.1002/jps.22729. Epub 2011 Aug 23.
9
Peroxide formation in polysorbate 80 and protein stability.聚山梨醇酯80中过氧化物的形成与蛋白质稳定性
J Pharm Sci. 2002 Oct;91(10):2252-64. doi: 10.1002/jps.10216.
10
Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis.重组人睫状神经营养因子在肌萎缩侧索硬化症患者中的毒性和耐受性
Neurology. 1996 Nov;47(5):1329-31. doi: 10.1212/wnl.47.5.1329.

引用本文的文献

1
Oxidation of polysorbates - An underestimated degradation pathway?聚山梨酯的氧化——一种被低估的降解途径?
Int J Pharm X. 2023 Jul 27;6:100202. doi: 10.1016/j.ijpx.2023.100202. eCollection 2023 Dec 15.
2
Effects of polyol excipient stability during storage and use on the quality of biopharmaceutical formulations.多元醇辅料在储存和使用过程中的稳定性对生物制药制剂质量的影响。
J Pharm Anal. 2022 Oct;12(5):774-782. doi: 10.1016/j.jpha.2022.03.003. Epub 2022 Mar 24.
3
Photo-Oxidation of Therapeutic Protein Formulations: From Radical Formation to Analytical Techniques.
治疗性蛋白质制剂的光氧化:从自由基形成到分析技术
Pharmaceutics. 2021 Dec 28;14(1):72. doi: 10.3390/pharmaceutics14010072.
4
Protein Formulations Containing Polysorbates: Are Metal Chelators Needed at All?含有聚山梨酯的蛋白质制剂:真的需要金属螯合剂吗?
Antioxidants (Basel). 2020 May 20;9(5):441. doi: 10.3390/antiox9050441.
5
Effect of Chemical Oxidation on the Higher Order Structure, Stability, Aggregation, and Biological Function of Interferon Alpha-2a: Role of Local Structural Changes Detected by 2D NMR.化学氧化对干扰素 α-2a 的高级结构、稳定性、聚集和生物学功能的影响:通过 2D NMR 检测到的局部结构变化的作用。
Pharm Res. 2018 Oct 15;35(12):232. doi: 10.1007/s11095-018-2518-y.
6
Comparative Effects of Metal-Catalyzed Oxidizing Systems on Carbonylation and Integrity of Therapeutic Proteins.金属催化氧化系统对治疗性蛋白质羰基化和完整性的比较影响
Pharm Res. 2016 Feb;33(2):526-39. doi: 10.1007/s11095-015-1807-y. Epub 2015 Oct 23.
7
Mechanism of Decarboxylation of Pyruvic Acid in the Presence of Hydrogen Peroxide.过氧化氢存在下丙酮酸的脱羧机制
J Pharm Sci. 2016 Feb;105(2):705-713. doi: 10.1002/jps.24653. Epub 2016 Jan 29.
8
Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration.开发一种稳定的低剂量无糖基化抗体制剂,以尽量减少静脉给药期间的蛋白质损失。
MAbs. 2015;7(4):792-803. doi: 10.1080/19420862.2015.1046664.
9
Physicochemical and formulation developability assessment for therapeutic peptide delivery--a primer.用于治疗性肽递送的物理化学与制剂可开发性评估——入门指南
AAPS J. 2015 Jan;17(1):144-55. doi: 10.1208/s12248-014-9688-2. Epub 2014 Nov 15.
10
Effect of polysorbate 80 quality on photostability of a monoclonal antibody.聚山梨酯 80 质量对单克隆抗体光稳定性的影响。
AAPS PharmSciTech. 2012 Jun;13(2):422-30. doi: 10.1208/s12249-012-9759-6. Epub 2012 Feb 24.